The 8765delAG Mutation in BRCA2 Is Common among Jews of Yemenite Extraction  by Lerer, Israela et al.
272 Letters to the Editor
Figure 1 a, SSCA. The arrow indicates the fragment with mo-
bility shift in patient III-1 of family BC10; and the other lanes contain
DNA samples of unrelated BC/OC patients. PCR primers for ampli-
fication of exon 20 were retrieved from the Breast Cancer Information
Core (1997); they are 20F, 5′-cactgtgcctggcctgatac-3′; and 20R, 5′-
atgttaaattcaaagtctcta-3′. Amplification conditions were 35 cycles of
94C for 30 s, 55C for 1 min, and 72C for 30 s; the size of the PCR
product was 296 bp. SSCA was performed as described elsewhere
(Zlotogora et al. 1995). b, Sequence of the 8765delAG mutation in
exon 20 of BRCA2 The PCR fragments with mobility shift in SSCA
were separated on 8% polyacrylamide gel, were excised from the gel,
and were run on 1% low-melt-temperature agarose in tris-acetate/
EDTA buffer. The DNA was cleaned with b-Agarase (NEB) and was
precipitated with isopropanol. The purified PCR fragments were se-
quenced by the dideoxy terminator cycle–sequencing method with
AmpliTaq DNA polymerase, FS (ABI Prism Ready Reaction Kit), and
then were analyzed by use of an automatic DNA sequencer (ABI
PRISM 310). The primers for sequencing were the same as those for
SSCA. c, Restriction analysis (with BsmAI) of the 8765delAGmutation
in family members of the identified carriers. U  uncut; N  normal;
and H  heterozygote. A mismatch was introduced into one of the
primers, and, as a result, the normal allele acquired a BsmAI restriction
site. The PCR primers were 20F and misR (5′-gctgcttccttttcttcg*t-3′),
and the size of the PCR product was 155 bp for the normal allele and
153 bp for the mutant allele. The PCR products were cut by BsmAI
(NEB) and were separated on NuSieve:agarose 3:1, were stained by
ethidium bromide, and were visualized under a UV lamp. In the het-
erozygote, two bands—153 bp and 132 bp—were seen.
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The 8765delAG Mutation in BRCA2 Is Common
among Jews of Yemenite Extraction
To the Editor:
The proportion of high-risk families with BRCA2 mu-
tations varies widely among populations. In Iceland, 8%
of unselected breast cancer (BC) patients and 64% of
patients with a definite family history of BC carry a
founder mutation in BRCA2—995del5 (Thorlacius et al.
1997). In the Ashkenazi Jews, the 6174delT mutation
is found in 24% of high-risk families and in 6% of
unselected BC patients (Abeliovich et al. 1997; Levy-
Lahad et al. 1997). Other ancient BRCA2 mutations
have been summarized by Szabo and King (1997).
Whereas some of the BRCA2 mutations were found in
BC-only families, including the majority of families with
male and female BC (Ford et al. 1998), other BRCA2
mutations, such as 6174delT, were found in BC/OC pa-
tients (i.e., those with BC and/or ovarian cancer [OC]).
In this letter, we describe the 8765delAG mutation in
BRCA2, a founder mutation in Jews of Yemenite origin.
During the screening of BC/OC patients for mutations
in the BRCA2 gene, PCR products of two patients (III-
9 in family BC10 and III-6 in family BC149) of Yemenite
extraction had mobility shifts, as determined by single-
strand conformation polymorphism (SSCA) (fig. 1a). Se-
quencing of these fragments revealed a deletion of 2 bp
(AG), one of three AGs starting at position 8761 (fig.
1b). The mutation was analyzed in genomic DNA of the
patients and of their family members, by a BsmAI re-
striction assay using a primer into which a mismatch
was introduced (fig. 1c). Patient II-4 in family BC703
and patient III-2 in family BC703, who were referred to
us because of their ethnic affiliation and positive family
history, were analyzed directly for the mutation. The
pedigrees of the three families are presented in figure 2.
We could not find any relationship among the three fam-
ilies. In families BC10 and BC149, only BC was re-
ported. In family BC703, one of the sisters had BC and
Letters to the Editor 273
Figure 2 Pedigrees of three families with the 8765delAG mu-
tation. Numbers in parentheses are the ages (in years) at diagnosis.
OC. In the three sibships there were 27 sisters (including
the index cases); 13 of them had BC, 2 had bilateral BC,
and 1 had BC and OC. The ages at diagnosis were 27–52
years, with a mean of 38.4 years. In all three families,
the fathers were apparent carriers. In family BC10, the
father had prostate cancer at the age of 60 years; in
family BC149, the father had BC at the age of 75 years.
The father (I-2) in family BC703 died at the age of 80
years of a cerebrovascular accident (stroke). Other can-
cers in the families were colon, neck, and laryngeal
cancer.
Nine BC patients of Yemenite origin (two of whom
were of mixed origin) and without family history of BC/
OC were analyzed for the 8765delAG mutation, and
none was found to be a carrier (table 1). In a sample of
140 healthy individuals of Yemenite origin, 1 carrier was
identified. The control DNA samples were collected from
unrelated and unselected individuals and were identified
interms of a code number. The frequency (0.7%) of the
8675delAG mutation that was observed in this sample
should be validated in a larger sample.
In addition, we tested the 8765delAG mutation in 41
Jewish BC patients—28 Ashkenazi Jews and 13 Se-
phardic and Oriental Jews (table 1)—who did not carry
any of the Ashkenazi founder mutations (185delAG and
5382insC, in BRCA1 ; and 6174delT, in BRCA2). This
group of patients met some of the criteria of hereditary
BC, such as positive family history of BC and/or OC in
three first-degree relatives, bilateral BC, both BC and
OC, BC and other primary cancer, or early age at di-
agnosis (!30 years); some of these patients have been
described elsewhere (Abeliovich et al. 1997). None of
these patients was a carrier of the 8765delAG mutation,
in support of the conclusion that the 8765delAG mu-
tation is confined to the Yemenite Jews.
The haplotypes (D13S171 and D13S260) of the chro-
mosomes bearing the 8765delAG mutation were ana-
lyzed in the three families (Lerer et al. 1994). The fam-
ilies all share the same haplotype: allele 7 with (CA)n5,
of D13S171, and allele 7, with (CA)n21, of D13S260.
In the anonymous carrier in the control group, we could
not determine the haplotype, but, in both loci, one of
the alleles was the same as that of the mutation’s hap-
lotype in the carrier patients. It thus has been concluded
that this is a founder mutation in the Yemenite Jews.
Among the Jewish people, the Yemenite Jews are a rel-
atively small group that, until their immigration to Israel
(during the last century), lived for many years in isola-
tion. The same mutation previously has been described
in two French Canadian patients (Phelan et al. 1996).
Family members of the two French Canadian patients
included 22 females with BC only, with mean age at
diagnosis 49.2 years. It thus seems that the risk that the
8765delAG mutation confers on carriers is mainly (but
not exclusively) with regard to BC. On the basis of the
limited number of patients studied, it seems that the
penetrance of the 8765delAGmutation is relatively high,
since the carriers had a strong family history of BC; 13
of 27 first-degree relatives had BC, and the age at di-
agnosis was very early.
It would be of interest to compare the haplotype of
the 8765delAG mutation in the Yemenite Jews with that
in the French Canadians, although it is highly unlikely
that the two groups share a mutation of common an-
cestral origin. Since the mutation is a deletion of AG in
a stretch of AGAGAG, the chance of recurrent mutation
resulting in AG deletion in this site might be higher than
that in a site having a single AG.
Nine BC patients of Yemenite origin—eight of whom
were diagnosed at age !50 years, including one patient
with bilateral BC and one patient with two other pri-
mary tumors—were not carriers of this mutation, which
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Table 1
Jewish BC Patients Who Were Analyzed for the 8765delAG Mutation, According to Clinical Diagnosis and Ethnic Affiliation
NO. (AGE [YEARS] AT DIAGNOSIS)
Ashkenazim Sephardim Orientals Yemenites Total
Positive family history 16 (40–64) 4 (40–64) 2 (40–64) 22
BC:
Unilateral 2 (25–29) 2a (25–29) 3 (25–29) 7 (20, 32, 35, 44, 46, 49, 55)b 14
Bilateral 9c 1 1 (29–65 [BC 40–43, OC 50–58])d 1 (BC 34, 38; OC 38) 11
BC and OC 1e 2
BC and other primary tumors 1f 1
Total 28 7 6 9 50
a One patient had a positive family history (i.e., at least three first-degree relatives with BC and/or OC).
b Two patients were of mixed origin (i.e., Yemenite/Ashkenazi and Yemenite/non-Ashkenazi).
c Four patients had a positive family history (i.e., at least three first-degree relatives with BC and/or OC).
d One patient had a positive family history (i.e., at least three first-degree relatives with BC and/or OC).
e One patient had a positive family history (i.e., at least three first-degree relatives with BC and/or OC).
f The other primary tumors were colon cancer and leukemia.
might indicate that the 8675delAG mutation is not the
only BRCA mutation in the Yemenite Jews. Indeed, one
BC patient of Yemenite origin (who was not included in
this study) was identified as a carrier of the 5382insC
mutation in BRCA1.
ISRAELA LERER,1 TIELING WANG,1 TAMAR PERETZ,2
MICHAL SAGI,1 LUNA KADURI,2 AVI ORR-URTREGER,3
JONA STADLER,4 HAIM GUTMAN,5 AND
DVORAH ABELIOVICH1
1Department of Human Genetics and 2Sharett
Institute of Oncology, Hadassah Hebrew University
Hospital, Hebrew University Medical School,
Jerusalem; and 3Genetic Institute and 4Breast Health
Center, Tel Aviv Suraski Medical Center, Tel Aviv;
and5Department of Surgery B, Rabin Medical Center,
Belinson Campus, and Tel Aviv University Sackler
School of Medicine, Tel Aviv
Electronic-Database Information
Breast Cancer Information Core, http://www.nhgri.nih.gov/ in-
tramural research/labtransfer/Bic
References
Abeliovich D, Kaduri L, Lerer I, Weinberg N, Amir G, Sagi
M, Zlotogora J, et al (1997) The founder mutations
185delAG and 5382insC in BRCA1 and 6174delT in
BRCA2 appear in 60% of ovarian cancer and 30% of early-
onset breast cancer patients among Ashkenazi women. Am
J Hum Genet 60:505–514
Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee
P, Bishop DT, et al (1998) Genetic heterogeneity and pen-
etrance analysis of the BRCA1 and BRCA2 genes in breast
cancer families. Am J Hum Genet 62:676–689
Lerer I, Meiner V, Pashut-Lavon I, Abeliovich D (1994) Mo-
lecular diagnosis of Prader-Willi syndrome: parent-of-origin
dependent methylation site and non-isotopic detection of
(CA)n dinucleotide repeat polymorphism. Am J Med Genet
52:79–84
Levy-Lahad E, Catane R, Eisenberg S, Kauffman B, Hornreich
G, Lishinsky E, Shohat M, et al (1997) Founder BRCA1
and BRCA2 mutations in Ashkenazi Jews in Israel: fre-
quency and differential penetrance in ovarian cancer and in
breast-ovarian cancer families. Am J Hum Genet 60:
1059–1067
Phelan CM, Lancaster JM, Tonin P, Gumbs C, Cochran C,
Carter R, Ghadirian P, et al (1996) mutation analysis of the
BRCA2 gene in 49 site specific breast cancer families. Nat
Genet 13:120–122
Szabo CI, King M-C (1997) Population genetics of BRCA1
and BRCA2. Am J Hum Genet 60:1013–1020
Thorlacius S, Sigurdsson S, Bjarnadottir H, Olafsdottir G, Jon-
asson JG, Tryggvadottir L, Tulinius H, et al (1997) Study
of a single BRCA2 mutation with high carrier frequency in
a small population. Am J Hum Genet 60:1079–1084
Zlotogora J, Lerer I, Bar-David S, Ergaz Z, Abeliovich D
(1995) Homozygosity for Waardenburg syndrome. Am J
Hum Genet 56:1173–1178
Address for correspondence and reprints: Dr. Dvorah Abeliovich, Department
of Human Genetics, Hadassah University Hospital, Ein Kerem, P.O. Box 12000,
Jerusalem, Israel 91120. E-mail: dvoraha@cc.huji.ac.il
 1998 by The American Society of Human Genetics. All rights reserved.
0002-9297/98/6301-0041$02.00
Am. J. Hum. Genet. 63:274–279, 1998
Localization of a Gene (CORD7) for a Dominant
Cone-Rod Dystrophy to Chromosome 6q
To the Editor:
The cone-rod dystrophies are a heterogeneous group of
retinal disorders, often leading to registrable blindness,
that are characterized by an initial loss of cone photo-
